Opendata, web and dolomites

WASABI

Towards the Wider uptake of Arterial Stiffness As a BIomarker for cardiovascular diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 WASABI project word cloud

Explore the words cloud of the WASABI project. It provides you a very rough idea of what is the project "WASABI" about.

niche    individuals    signal    local    select    carotid    complior    of    pulse    medical    expensive    elaborate    intellectual    rights    methodology    undertaking    distribute    contexts    assemble    mellitus    demonstration    plan    mo    serial    graph    device    actions    initiated    alam    appropriate    measuring    velocity    bplab    cardiologists    lower    move    physicians    standard    business    estimations    technologies    hypertension    complicate    wave    practitioners    intend    pwv    sphygmocor    tool    renal    aortic    suitable    arteriograph    clinical    elevated    create    affordable    predict    bil    notably    arterial    questionable    stage    shown    diabetes    biomarker    transform    blood    sensors    pressure    secure    vasotens    cardiovascular    artery    stiffening    mortality    market    pulsepen    population    property    either    innovation    gold    recognised    relatively    stiffness    alternative    sensor    mainly    easier    model    everyday   

Project "WASABI" data sheet

The following table provides information about the project.

Coordinator
ALAM MEDICAL 

Organization address
address: 112 AVENUE DE PARIS
city: VINCENNES
postcode: 94300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.complior.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-12-01   to  2016-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALAM MEDICAL FR (VINCENNES) coordinator 50˙000.00

Map

 Project objective

Aortic stiffness is a recognised cardiovascular biomarker and measurement of aortic pulse wave velocity (PWV) is the gold standard methodology to assess large artery stiffening. Elevated aortic PWV has been shown to predict cardiovascular, and in some cases all cause, mortality in individuals with end-stage renal failure, hypertension, diabetes mellitus, as well as in the general population. However, at present, the role of measurement of PWV as a general clinical tool remains to be established, particularly because devices on the market (ALAM Medical Complior, SphygmoCor, Mo-bil-O-Graph, PulsePen, BPLab Vasotens, or Arteriograph) are either complicate to use and relatively expensive, or only provide lower cost estimations whose clinical value is questionable.

That’s why ALAM Medical has initiated an innovation project whose objective is to scale up the use of arterial stiffness as a biomarker, notably by investigating alternative sensors so as to create and distribute an easier to use and more affordable device measuring gold standard aortic stiffness and local carotid stiffness while being suitable for everyday use in numerous medical contexts. By providing a medical device with such characteristics, as well as by undertaking appropriate market awareness actions, we intend to transform our existing niche market, mainly composed of clinical researchers, into a large-scale market composed of clinical practitioners, cardiologists or physicians: arterial stiffness measurements have the potential to move from research to standard medical practice, on the model of blood pressure measurements.

To this aim, during project Phase 1, ALAM Medical will select the most appropriate sensor technology, secure intellectual property rights on sensor and signal processing technologies, assemble pre-serial devices, elaborate a more detailed business plan, and design a large-scale demonstration study (included in project Phase 2).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "WASABI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "WASABI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More